Home › NDC Lookup › Ingredients › Phenylephrine Hcl › 70677-1152-01
⚪image loading
(from DailyMed)

Nasal Decongestant PE Maximum Strength Phenylephrine HCl 10 mg Tablet, Film Coated, 18-count

by Strategic Sourcing Services LLC · 1 BLISTER PACK in 1 CARTON (70677-1152-1) / 18 TABLET, FILM COATED in 1 BLISTER PACK
NDC 70677-1152-01
🏷️ FDA NDC (as labeled) 70677-1152-1 billing pads the package segment with a zero
This package
Contains18-count Cost per ea$0.0496 NADAC Per package$0.89 / 18 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.4617/unit — full pricing hub ↓
Also comes in: 18 tablets 70677-1152-02
OTC On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 70677-1152-1
Product NDC 70677-1152
11-digit billing NDC 70677115201
NCPDP billing unit EA — each (per item)
RxCUI 1049182
UNII 04JA59TNSJ
UPC 0010939958167
Application # M012
SPL Set ID 8460d4f9-8d7b-4ae4-8047-c2010d9c8013
Established class (EPC) alpha-1 Adrenergic Agonist
Mechanism of action Adrenergic alpha1-Agonists
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-04-05
Route ORAL
Dosage form TABLET, FILM COATED
Substance PHENYLEPHRINE HYDROCHLORIDE
GPI-14 42101040100310
GCN Seq No 058496
GCN 23944
HICL code 002087
Ingredient (HICL) Phenylephrine Hcl
HIC1 code B
Therapeutic class — broad (HIC1) Respiratory System
HIC2 code B6
Therapeutic class — intermediate (HIC2) Drugs Affecting The Trachea And Bronchi (Cont3)
HIC3 code B6V
Therapeutic class — specific (HIC3) Decongestants, Oral
AHFS code 12:12.04.00
AHFS class Alpha-Adrenergic Agonists (12:12)
FDB label name FT NASAL DECONG PE 10 MG TAB
FDB brand name Nasal Decongestant Pe
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 70677-1152-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70677-1152-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the alpha-1 Adrenergic Agonist class.

Pharmacologic class alpha-1 Adrenergic Agonist
Drug family (ATC) Sympathomimetics excl. antiglaucoma preparations, Adrenergic and dopaminergic agents, Other agents for treatment of hemorrhoids and anal fissures for topical use
How it works Adrenergic alpha1-Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerStrategic Sourcing Services LLC
FDA applicationM012 (OTC MONOGRAPH DRUG)
Labeler code70677
First marketedApr 2023
Product typeHuman Otc Drug
Portfolio316 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name FT NASAL DECONG PE 10 MG TAB Ingredient Phenylephrine Hcl
📖 What it is MedlinePlus · NLM

Phenylephrine is used to relieve nasal discomfort caused by colds, allergies, and hay fever. It is also used to relieve sinus congestion and pressure. Phenylephrine will relieve symptoms but will not treat the cause of the symptoms or speed recovery. Phenylephrine is in a class of medications called nasal decongestants. It works by reducing swelling of the blood vessels in the nasal passages.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Yes, it's the same active ingredient, but used in very different ways depending on the form. The nasal spray delivers a tiny amount directly to the nasal lining to temporarily shri...
  • I see phenylephrine in nasal sprays at the pharmacy AND as an IV drug in the hospital — is it really the same medication?
  • You should check with your doctor first. Phenylephrine constricts blood vessels, which can raise blood pressure and put extra strain on the heart — even from a nasal spray. If you...
  • Can I use the nasal spray if I have high blood pressure or heart disease?
📖 Read our full Phenylephrine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII K679OBS311
    Carboxymethylcellulose sodium is a plant-derived thickening agent made from cellulose. In medicines, it acts as a binder to hold ingredients together, a disintegrant to help the tablet break apart, or a thickener in liquids.
  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII LX22YL083G
    A simple sugar derived from corn or other sources. It acts as a filler to give the medicine bulk and volume, and as a sweetener to improve taste in oral medications.
  • UNII O7TSZ97GEP
    A mineral compound that serves as a filler and binding agent in tablets and capsules. It adds bulk to the medicine and helps hold ingredients together during manufacturing.
  • UNII WZB9127XOA
    A synthetic red dye used to color medications and make them easier to identify. It serves as a colorant in tablets, capsules, and liquid formulations.
  • UNII 1DI56QDM62
    A natural fatty substance from soybeans that helps mix oil and water-based ingredients together. It acts as an emulsifier and lubricant in medicines to improve texture and help the product break down properly in your body.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII 7CVR7L4A2D
    A starch-derived carbohydrate produced by breaking down corn, potato, or tapioca starch. It functions as a filler and binder to give the medicine bulk and texture, and sometimes as a mild sweetener or texture enhancer in powders and tablets.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
  • UNII B22547B95K
    A salt derived from citric acid that helps maintain the proper acid-base balance in the medicine. It's used as a buffer to keep the product stable and at the right pH level.

12 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescroscarmellose sodium, dextrose monohydrate, dibasic calcium phosphate dihydrate, FD&C red #40, lecithin, magnesium stearate, maltodextrin, microcrystalline cellulose, silicon dioxide, sodium carboxymethylcellulose, sodium citrate dihydrate, titanium dioxide

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.050 $0.89 / 18 tablets
Medicaid paysCMS SDUD · 12 mo $0.4617 $8.31 / 18 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2023 Jan 2026 May 2026 Sep 2026 $0.052 $0.048
▲ Up 4% over the last 13 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Nasal Decongestant PE Maximum Strength 10 mgthis 70677-1152-01 Strategic 18 tablets $0.050 — Availability likely —
Nasal Decongestant PE 10 mg 00363-4531-07 Walgreen 18 tablets — — FDA listed —
PhysiciansCare Sinus Non-Drowsy 10 mg 00924-0133-01 Acme 1 tablet — — FDA listed —
Sinus Pressure and Congestion Relief PE Maximum Strength 10 mg 11822-4530-02 Rite 24 tablets — — FDA listed —
Nasal Decongestant PE 10 mg 21130-0453-07 Better 18 tablets — — FDA listed —
Sinus Decongestion PE 10 mg 30142-0534-07 Kroger 18 tablets — — FDA listed —
Sinus Congestion 10 mg 30142-0853-07 Kroger 18 tablets — — FDA listed —
PE Sinus Congestion 10 mg 36800-0704-07 Topco 18 tablets — — FDA listed —
Nasal Decongestant PE 10 mg 37808-0453-23 H 24 tablets — — FDA listed —
Nasal Decongestant PE 10 mg 37835-0651-01 Bi-Mart 100 tablets — — FDA listed —
Medi-First Sinus Decongestant 10 mg 47682-0809-13 Unifirst 1 tablet — — FDA listed —
Medi-First Plus Sinus Decongestant 10 mg 47682-0990-33 Unifirst 1 tablet — — FDA listed —
Unishield Sinus Decongestant 10 mg 49314-2083-03 Unishield 1 tablet — — FDA listed —
Pseudo Time Pe 10 mg 49483-0234-00 TIME 100000 tablets — — FDA listed —
Good Sense Nasal Decongestant PE 10 mg 50090-3659-00 A-S 36 tablets — — FDA listed —
Phenylephrine HCl Maximum Strength 10 mg 50090-5606-00 A-S 18 tablets — — FDA listed —
Nasal Decongestant Pe 10 mg 50090-7449-00 A-S 18 tablets — — FDA listed —
Sudafed PE Sinus Congestion 10 mg 50580-0437-01 Kenvue 18 tablets — — FDA listed —
Sinus Congestion 10 mg 50844-0493-08 L.N.K. 24 tablets — — FDA listed —
Suphedrine PE Sinus Congestion Non-Drowsy 10 mg 55301-0753-23 ARMY 24 tablets — — FDA listed —
SU PHEDRINE PE Non-Drowsy, Maximum Strength 10 mg 57243-0453-44 Salado 18 tablets — — FDA listed —
Su Phedrine Pe Sinus Congestion 10 mg 57243-0953-44 Salado 18 tablets — — FDA listed —
Phenylephrine Hydrochloride 10 mg 57631-0018-00 InvaTech 30000 tablets — — FDA listed —
Nasal Decongestant PE Non-Drowsy Maximum Strength 10 mg 63868-0144-19 CHAIN 18 tablets — — FDA listed —
Nasal Decongestant PE Maximum Strength 10 mg 67091-0207-18 WinCo 18 tablets — — FDA listed —
Nasal Decongestant PE Maximum Strength Non-Drowsy 10 mg 69168-0272-17 Allegiant 300 tablets — — FDA listed —
Redicare Nasal and Sinus Decongestant 10 mg 71105-0272-02 Redicare 100 tablets — — FDA listed —
Gencare-Nasal Decongestant PE 10 mg 72090-0025-01 Pioneer 300 tablets — — FDA listed —
Gencare-Nasal Decongestant PE 10 mg 72090-0039-01 Pioneer 300 tablets — — FDA listed —
Crane Safety Sinus Decongestant 10 mg 73408-0990-33 Crane 1 tablet — — FDA listed —
ValuMeds Nasal Decongestant Phenylephrine HCl 10 mg 82725-1111-01 Cabinet 300 tablets — — FDA listed —
Goodmeds Non-Drowsy Nasal Decongestant PE 10 mg 82725-4111-01 Cabinet 365 tablets — — FDA listed —
Sinus Congestion 10 mg 83324-0073-18 Chain 18 tablets — — FDA listed —
Phenylephrine Hydrochloride 10 mg 83586-0010-00 HHH 130000 tablets — — FDA listed —
Nasal Decongestant PE 10 mg 83586-0160-01 HHH 100 tablets — — FDA listed —
Nasal Decongestant PE 10 mg 84324-0010-01 NUVICARE 100 tablets — — FDA listed —
Nasal Decongestant PE Maximum Strength 10 mg 85766-0178-18 Sportpharm 18 tablets — — FDA listed —
Medi-First Plus Sinus Decongestant 10 mg 85766-0182-01 Sportpharm 1 tablet — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2023
On the market since
Apr 2023
📍
2026
Currently FDA-listed
3 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 70677-1152-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
56
Units reimbursed last 4 qtrs
1.4K
Gross reimbursed last 4 qtrs
$624.62
Avg / prescription
$11.15
Avg / unit
$0.4617
Latest quarter Q1 2026
12Rx
Medicaid pays / ea
$0.4617
gross reimbursed
vs
NADAC / ea
$0.0496
acquisition cost
=
Spread
+$0.4121
+831% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
100% FFS
Fee-for-service · 56 Rx Managed care · 0 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 1,353 units · 3.5 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
3.53.5
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 California 3.5 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
Drug total (last 4 qtrs): 215 Rx · 6,591 units · $85,868 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Phenylephrine HCl (matched by generic name) — the program that covers self-administered drugs. 4 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Phenylephrine HCl. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$3.7K
Claims incl. refills
148
Beneficiaries
134
Spend / beneficiary
$27.89
Spend / claim
$25.25
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
70677-1152-01 You're viewing this 1 BLISTER PACK in 1 CARTON (70677-1152-1) / 18 TABLET, FILM COATED in 1 BLISTER PACK $0.0496 / ea $0.89 2023-04-05 Active
70677-1152-02 2 BLISTER PACK in 1 CARTON (70677-1152-2) / 18 TABLET, FILM COATED in 1 BLISTER PACK $0.0496 / ea $1.78 2023-04-05 Active

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.0496 NADAC).

This pack accounts for about 26% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in NDC 70677-1152-01?
NDC 70677-1152-01 is a 18-count package — 1 blister pack in 1 carton / 18 tablet, film coated in 1 blister pack.
What NDC number is used to bill for this package of Nasal Decongestant PE Maximum Strength Phenylephrine HCl 10 mg Tablet, Film Coated?
Bill NDC 70677-1152-01 — the 11-digit billing format is 70677115201. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 23 words ▾

Uses temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies temporarily relieves sinus congestion and pressure

⏱️ Dosage and Administration 31 words ▾

Directions adults and children 12 years and over: take 1 tablet every 4 hours. Do not take more than 6 tablets in 24 hours. children under 12 years: ask a doctor

⚠️ Warnings 145 words ▾

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Ask a doctor before use if you have heart disease diabetes thyroid disease high blood pressure difficulty in urination due to enlargement of the prostate gland When using this product do not exceed recommended dosage.

Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur symptoms do not improve within 7 days or occur with fever If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

📦 Storage and Handling 36 words ▾

Other information TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F) see end flap for expiration date and lot number

🧪 Active Ingredient 9 words ▾

Active ingredient (in each tablet) Phenylephrine HCl 10 mg

🧪 Inactive Ingredients 28 words ▾

Inactive ingredients croscarmellose sodium, dextrose monohydrate, dibasic calcium phosphate dihydrate, FD&C red #40, lecithin, magnesium stearate, maltodextrin, microcrystalline cellulose, silicon dioxide, sodium carboxymethylcellulose, sodium citrate dihydrate, titanium dioxide

🎯 Purpose 3 words ▾

Purpose Nasal decongestant

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.